about
CIViC databaseDrug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Clinical and biological significance of RAS mutations in multiple myeloma.Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple MyelomaTargeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myelomaImpact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03.Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.Plasma cell leukemia.The dichotomy of p53 regulation by noncoding RNAs.p53 abnormalities and potential therapeutic targeting in multiple myeloma.Implications of heterogeneity in multiple myeloma.Serial exome analysis of disease progression in premalignant gammopathies.Negative regulation of the tumor suppressor p53 gene by microRNAs.Mutations in TP53 are exclusively associated with del(17p) in multiple myelomaThe DAC system and associations with multiple myeloma.Regulation of p53-targeting microRNAs by polycyclic aromatic hydrocarbons: Implications in the etiology of multiple myeloma.Targeting p53 by small molecules in hematological malignancies.Anaplastic plasmacytoma of mouse--establishing parallels between subtypes of mouse and human plasma cell neoplasia.Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.Genetic events in the pathogenesis of multiple myeloma.Genetic and molecular mechanisms in multiple myeloma: a route to better understand disease pathogenesis and heterogeneity.The molecular characterization and clinical management of multiple myeloma in the post-genome era.Genetic aberrations and survival in plasma cell leukemiaPRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation.DNA methylation of microRNA genes in multiple myeloma.Emerging pathways as individualized therapeutic target of multiple myeloma.Staging and prognostication of multiple myelomaPlasma cell leukemia: from biology to treatment.Mechanisms and clinical applications of chromosomal instability in lymphoid malignancy.DNA methylation of tumor suppressor protein-coding and non-coding genes in multiple myeloma.The novel autophagy inhibitor elaiophylin exerts antitumor activity against multiple myeloma with mutant TP53 in part through endoplasmic reticulum stress-induced apoptosis.MicroRNA expression patterns and target prediction in multiple myeloma development and malignancy.RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.Gene integrated set profile analysis: a context-based approach for inferring biological endpointsA preliminary study of the effect of curcumin on the expression of p53 protein in a human multiple myeloma cell line.Mutational landscape reflects the biological continuum of plasma cell dyscrasias.p53 haploinsufficiency and functional abnormalities in multiple myeloma.Mutational analysis of TP53 gene in Tunisian familial hematological malignancies and sporadic acute leukemia cases.Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature.
P2860
Q27612411-9136E990-7822-4C6A-A6AA-C031E859390CQ27692033-ABBEB593-FFA1-427F-809C-4F29AC72FE2CQ27851434-C5160BB3-9DAF-46AC-A018-79E6267A9C86Q28074490-B3EE7901-B0CE-4E6B-B593-4A5A1E1EB457Q28479002-B1D72CC9-18E3-4AB1-ABA5-D54D3E067A65Q30424188-E90CB70C-94D9-4036-B4A9-3649710A7B50Q31154933-F543A81D-1DAE-4091-BDFD-602A3D6ED485Q33393995-76BB1200-7DFC-4B55-945A-263CB877FB98Q33668469-EF8EAF94-404E-4303-AE91-783BDA0DF62DQ33852683-6216A50A-F443-4A31-95EB-4BEF786FEFECQ33914824-3360FEBA-67E1-4C98-A922-D00CE2AD5F0DQ34079934-0EF3496C-358F-4E88-A117-9EC2ECC0562EQ34142778-1BFD9CD6-3224-46AD-A303-B2EF68C1401DQ34255215-6D63BE9D-879D-4638-B92A-79CE1A86F7C9Q34414447-8E443AC6-7D56-4677-A13D-F433DF7A6B60Q34466211-834F9B30-2462-4E4E-896D-6BE41CAE4B7EQ34636996-CF4F9DB3-426D-46B2-B447-FD660035BE6CQ35055356-6B69C71A-8D32-46ED-84F8-2835C681BC4CQ35678607-6A69E84F-CDF0-404E-9138-49702EAD9F37Q36380235-C1A9C19C-5616-4251-BBAC-588BDDFF9CFBQ36925154-3E0479C4-8C5D-4E2A-A047-981B0C2BB30CQ36939043-5FDDF613-26D7-435D-A653-F921D33C2795Q37486780-FF5383F2-3CCA-4308-8A4A-44753A05044EQ37641688-9831C5B1-2123-4531-A9A6-B5E9F2D61450Q38020153-1882A843-AE8D-4DA1-8A0F-9EFB2F9C1156Q38112176-14D70AFB-E1BC-4451-944A-6300975FDA05Q38183871-56ACAAD7-A892-4926-9813-963871F5546CQ38380625-57C8169D-13A5-4B28-9043-03549DA2B7E7Q38504989-6D048DAC-98AD-4FB5-A9BA-E2EB0232548EQ38595057-AD69FA39-FED0-4BEF-B941-FD5349132F43Q38674188-4C137ACC-3A95-4DE7-A5C3-85466616D1CDQ38689170-C62827C9-ABB8-4681-A080-3DA169230258Q38709232-EA440880-D1F7-4AE4-B2F4-8E44D80113EDQ38798005-E0A6FA96-5D08-469D-8F64-B41F8C8D04E1Q38897664-53158231-63EE-4587-9651-CB9EDD0DE108Q38943973-9BAE3CE7-3D8B-49D3-9AB5-6250CAE3D638Q39015919-EA08A00C-1C5D-4735-85DA-C38B319D73A9Q39399293-58586966-A954-4BCC-B96B-085B6361E567Q39685958-7068C44A-A8FF-4457-A9EB-9C4C9BF3883AQ40002181-11C2A80D-EA57-4F15-996E-F191366588DF
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Clinical significance of TP53 mutation in myeloma.
@ast
Clinical significance of TP53 mutation in myeloma.
@en
Clinical significance of TP53 mutation in myeloma.
@nl
type
label
Clinical significance of TP53 mutation in myeloma.
@ast
Clinical significance of TP53 mutation in myeloma.
@en
Clinical significance of TP53 mutation in myeloma.
@nl
prefLabel
Clinical significance of TP53 mutation in myeloma.
@ast
Clinical significance of TP53 mutation in myeloma.
@en
Clinical significance of TP53 mutation in myeloma.
@nl
P2093
P3181
P356
P1433
P1476
Clinical significance of TP53 mutation in myeloma.
@en
P2093
B Van Ness
K Henderson
N Gonzalez-Paz
S Van Wier
T Price-Troska
P2888
P3181
P356
10.1038/SJ.LEU.2404524
P577
2007-03-01T00:00:00Z
P5875
P6179
1014703665